Aldeyra Therapeutics Inc ALDX:NASDAQ

Last Price$7.68NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/26/21

Today's Change-0.24(3.03%)
Bid (Size)$7.59 (25)
Ask (Size)$9.00 (4)
Day Low / High$7.32 - 8.25
Volume693.3 K
 

View Biotechnology IndustryPeer Comparison as of 11/26/2021

 

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $7.68
Change: -0.24 (3.03%)
Volume: 693.3 K
1:00PM ET 11/26/2021
 
 

CytomX Therapeutics Inc ( NASDAQ )

Price: $6.75
Change: -0.29 (4.12%)
Volume: 829.2 K
1:00PM ET 11/26/2021
 
 

CEL-SCI Corp ( NYSE MKT LLC )

Price: $10.22
Change: -0.66 (6.07%)
Volume: 947.8 K
5:00PM ET 11/26/2021
 
 

Omeros Corp ( NASDAQ )

Price: $7.43
Change: -0.37 (4.74%)
Volume: 380.4 K
1:00PM ET 11/26/2021
 
 

Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $9.24
Change: -0.90 (8.88%)
Volume: 236.9 K
1:00PM ET 11/26/2021
 

Read more news Recent News

Aldeyra Therapeutics Completes Enrollment in Dry Eye Disease Phase 3 Trial
3:34PM ET 11/09/2021 MT Newswires

Aldeyra Therapeutics (ALDX) said Tuesday that it completed enrollment in a phase 3 trial of 0.25% reproxalap ophthalmic solution for the treatment of...

Aldeyra Therapeutics Says Reproxalap Ophthalmic Solution Achieves Primary Endpoint in Dry Eye Disease Trial
11:55AM ET 11/02/2021 MT Newswires

Aldeyra Therapeutics (ALDX) said Tuesday that a midstage clinical trial of its reproxalap ophthalmic solution in patients with dry eye disease achieved its...

-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Posts Q3 Loss $-0.27
7:10AM ET 10/28/2021 MT Newswires

...

-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Reports Q2 Loss $-0.28
7:13AM ET 8/05/2021 MT Newswires

...

Company Profile

Business DescriptionAldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA. View company web site for more details
Address131 Hartwell Avenue
Lexington, Massachusetts 02421
Phone+1.781.761.4904
Number of Employees19
Recent SEC Filing11/09/20218-K
President, Chief Executive Officer & DirectorTodd C. Brady
Chief Financial OfficerJoshua Reed
Vice President & ControllerBruce Greenberg
Senior Vice President-Clinical DevelopmentJames A. Gow

Company Highlights

Price Open$8.25
Previous Close$7.92
52 Week Range$6.47 - 15.95
Market Capitalization$446.1 M
Shares Outstanding58.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.06
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-33.38%

Analyst Ratings as of 11/13/2021

Buy
9
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset